Influx Healthtech Limited · NSE:INFLUX
Influx Healthtech — FY2026 Earnings Presentation
37 slides from Influx Healthtech's earnings presentation, May 21, 2026
Slide 1: Exchange submission cover letter
May 21, 2026 To, Listing Department, National Stock Exchange Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai-400 051 Scrip Code – INFLUX Dear Sir/Ma’am, Sub.: Submission of Investor Presentation for Investor Conference Call scheduled to be held on May 22, 2026. Ref.: R
Slide 2: Investor Presentation – FY26 Earnings Update
INVESTOR PRESENTATION – FY26 EARNINGS UPDATE
Slide 3: Agenda
Agenda 1. Performance Update 2. About Influx Healthtech Limited 3. Competitive Moats 4. Investment Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. Annexures
Slide 4: Executive Summary – FY26
Executive Summary – FY26 Revenue and Profitability Return and Capital Presence and Capacity Revenue from Operations Return on Equity (RoE) Product Range INR 146.8 crs. 20.4% 3,428 Up 40% YoY Vs 37.0% in FY25 Vs 3,559 in FY25 EBITDA Return on Capital Employed (RoCE) Client Retention INR 29.9 crs. 25.
Slide 5: Performance Update and Management Commentary – FY26
Performance Update and Management Commentary – FY26 ▪ Secured a 5-year FSSAI license for the new rented facility to manufacture health and dietary supplements ▪ Capacity expansion - Invested ₹60 Lakhs to boost tablet capacity from 20,000 bottles to Business Updates 30,000-35,000 bottles per day ▪ In
Slide 6: Revenue Split Across Segments
Revenue Split Across Segments (₹ crores) Nutraceuticals Cosmetics Ayurvedic Others1 40.3% 15.8% 88.9% 18.7% 131.9 6.1 7.4 1.4 94.0 6.4 1.2 71.9 4.5 3.5 3.2 4.0 0.7 2.0 0.7 49.6 H2FY25 H2FY26 FY25 FY26 H2FY25 H2FY26 FY25 FY26 H2FY25 H2FY26 FY25 FY26 H2FY25 H2FY26 FY25 FY26 1% 1% 90% 90% 3% FY25 4% FY
Slide 7: Agenda
Agenda 1. Performance Update 2. 2. About About Influx Influx Healthtech Healthtech Limited Limited 3. Competitive Moats 4. Investment Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. Annexures
Slide 8: Formulation Driven, Brand Focused Healthcare Company
Formulation Driven, Brand Focused Healthcare Company About Influx Healthtech Limited Revenue Mix – FY26 (%) ▪ Founded in 2020 by Dr. Munir Chandniwala, Influx Healthtech is a contract development Ayurvedic, 4% Veterinary & Homecare, 1% and manufacturing organization (CDMO) specializing in nutraceuti
Slide 9: Strategic Milestones
Strategic Milestones Transitioned into a Started snacking and Became public private limited gummies production limited company company lines 2003 2021 2024 2026 2020 2023 2025 Started Entered industry manufacturing units Acquired additional Introduced "Quick Snap" for nutraceuticals, land in Palghar
Slide 10: Agenda
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. 3. Competitive Competitive moats Moats 4. Investment Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. Annexures
Slide 11: Sustainable Competitive Moats
Sustainable Competitive Moats Well-diversified product portfolio Formulation driven innovation Robust and integrated business model Strong clientele across geographies and industries Capacity expansion for sustained growth Industry leading certification & compliance systems Passionate and purpose-dr
Slide 12: Well-Diversified Product Portfolio
Well-Diversified Product Portfolio Home Care Dietary/Nutritional Supplements Veterinary Feeds 0.1% 1% 90% 147crs. FY26 revenue 4% Ayurvedic /Herbal 5% Cosmetics Our product lines reflect our dedication to bringing cutting edge, science-backed health solutions to consumers Note: Chart is not to scale
Slide 13: Actively Focused on Expanding Our Product Portfolio
Actively Focused on Expanding Our Product Portfolio 2026 • Quick snapTM technology • MMTC technology 2025 • Functional beverages 2024 • Pet food for cats • Ayurvedic gummies • Nutritional oral gel 2021 2023 • Oral dissolving powder • Pet food for dogs • Nutritional gummies 2022 • Wafer protein bars
Slide 14: In-house F&D Unit: Key Driver in Creating Innovative, Market-Ready Solutions
In-house F&D Unit: Key Driver in Creating Innovative, Market-Ready Solutions ▪ Provide development services including formulation development, process development and analytical development ▪ In-house formulation & development (F&D) team focused on creating new formulations based on current health t
Slide 15: Supporting Clients Across all Stages of Development and Manufacturing
Supporting Clients Across all Stages of Development and Manufacturing Contact Influx Sample preparation Label designing Finished Healthtech product New product idea Pricing Finalizing packaging Commercial scale production 14
Slide 16: Strong Clientele Across Geographies and Industries
Strong Clientele Across Geographies and Industries Number of Clients Marquee Clients 718 636 538 559 FY23 FY24 FY25 FY26 Develop reliable, palatable formulations that ensure consumer acceptance and long-term client success Work closely with clients to refine formulations for feasibility, cost effici
Slide 17: Capacity Expansion for Sustained Growth
Capacity Expansion for Sustained Growth Nutraceuticals Cosmetics & Ayurvedic Pet Supplements & Homecare Capacity Utilization: 72% Capacity Utilization: 55% Capacity Utilization: 75% 300 7,000 1,150 17,000 3,150 1,800 1,500 10,000 2,000 FY25 Addition FY26 FY25 Addition FY26 FY23 Addition FY26 ▪ Expan
Slide 18: Strategic Reallocation of IPO Funds
Strategic Reallocation of IPO Funds Particulars Proposed Utilisation Utilisation Till Date Unutilised Till Date Reallocated In Reallocated Out (In ₹ lakhs) Nutraceutical 2,249.11 1,176.18 1,072.93 1,796.37 (393.36) Division Veterinary Food 1,148.58 138.00 1,010.58 - (549.35) Division Homecare & Cosm
Slide 19: Massive Increase in Output Post Commissioning of Our New Capacity
Massive Increase in Output Post Commissioning of Our New Capacity Unit – 1 Nutraceuticals Capacities Commercialized in H1FY26, Unit – 2 Cosmetics & ayurvedic Through Internal Accruals Multi-Line Production ▪ 480 kg/day: Tablet production ▪ 24,000 bottles/shift: Liquid production ▪ 32,000 sachets/shi
Slide 20: Capex Deployment Progressing as Planned
Capex Deployment Progressing as Planned Unit – 1 Nutraceuticals Unit – 2 CosmeticsMachinery & ayurvedicOrdered | Funded via IPO Proceeds Automated Beverage Manufacturing Line ▪ Capacity: 10,000 bottles/hour ▪ Supports both carbonated and non-carbonated beverage formats Sachet Card Machine (Single-Do
Slide 21: Industry Leading Certification and Compliance Systems
Industry Leading Certification and Compliance Systems Industry Leading Certifications and Accreditations Enhancing our Ability to Further Revenue Growth Adherence to High Quality Standards Prevents unsafe food from reaching consumers Reduces risks like contamination, errors, or unsafe products Build
Slide 22: Awards and Recognition
Awards and Recognition 2015 2016 2016 2018 2025 Best Nutraceutical Company of Best Sports Supplement Best Sports Supplement Innovative Nutraceuticals Grade A+ Exemplar the Year 2015 in 3rd Party Manufacturing Company of the Manufacturing Company of the of the Year, 2018. Certification, 2025. Certifi
Slide 23: Passionate and Purpose-Driven Team
Passionate and Purpose-Driven Team Dr. M.A. Chandniwala Mrs. Shirin Chandniwala Dr. A.A. Chandniwala Dr. Vipul Patel CA Mohmad Saleh Mutvalli (MD & Chairman) Whole-time Director Director Independent Director Independent Director Industry experience: 22+ years Industry experience: 12+ years Industry
Slide 24: Agenda
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. Competitive Moats 4. 4.Investment Investmentrationale Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. Annexures
Slide 25: Investment Rationale: Influx Healthtech Limited
Investment Rationale: Influx Healthtech Limited Diversified Product Portfolio Wide-Ranging Client Base Advanced Formulation Development Multi-nutritional tablets, dietary A strong presence across cosmetics, supplements, ayurvedic products, oral Specializes in formulation pharmaceuticals, and homecar
Slide 26: Agenda
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. Competitive Moats 4. Investment Rationale 5. 2. Historical 5. About business Influx Historical performance Healthtech Business Limited Performance 6. Select Financial Statement Data 7. Annexures
Slide 27: Historic Business Performance (1/3)
Historic Business Performance (1/3) Revenue from Revenue from Operations operations (₹ (₹ crs.) crs.) RevenueEBITDA from operations (₹ crs.) (₹ crs.) Revenue from PAToperations (₹ crs.) (₹ crs.) 147 30 21 100 105 21 17 13 11 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Revenue from Gross operations
Slide 28: Historic Business Performance (2/3)
Historic Business Performance (2/3) Revenue fromROE operations 1 (₹ crs.) Revenue from operations Debtor Days (₹ crs.) RevenueInventory from operations Days (₹ crs.) 113 112 49% 99 84 37% 58 20% 41 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 RevenueAsset from operations Turnover (₹ crs.) Revenue Ca
Slide 29: Historic Business Performance (3/3)
Historic Business Performance (3/3) Revenue fromConcentration Revenue operations (₹1 crs.) Revenue fromConcentration Supplier operations (₹1 crs.) Revenue Cash Flow from fromoperations Operations(₹ (₹crs.) crs.) 49% 39% 9 49% 36% 29% 7 48% 4 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Revenue from
Slide 30: Agenda
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. Competitive Moats 4. Investment Rationale 5. Historical Business Performance 2. 6.About Select Influx Healthtech Financial financial Limited Statement statement Data data 7. Annexures
Slide 31: Income Statement
Income Statement ₹ crores unless otherwise mentioned Particulars H2 FY26 H2 FY25 YoY change (%) FY26 FY25 YoY change (%) Revenue from operations 80.1 56.8 41% 146.8 104.9 40% Cost of materials consumed including finished goods and WIP 49.2 33.7 46% 86.7 63.4 37% Employee benefits expense 6.7 4.9 36%
Slide 32: Balance Sheet
Balance Sheet ₹ crores unless otherwise mentioned Assets FY26 FY25 PPE and intangible assets 27.6 18.8 Capital work-in-progress 3.5 0.0 Non-current assets 11.2 2.5 Cash and cash equivalents 25.2 1.9 Current investments 2.3 0.0 Short term loans and advances 3.9 0.8 Trade receivables 33.8 32.4 Invento
Slide 33: Cashflow Statement
Cashflow Statement ₹ crores unless otherwise mentioned Cashflow from operating activities FY26 FY25 Net Profit before tax & extraordinary items 27.2 17.7 Depreciation & amortization expenses 3.8 2.8 Other adjustment -0.6 0.2 Trade receivables -1.8 -16.6 Trade payables -10.3 15.4 Loans and advances -
Slide 34: Agenda – Annexures: Industry Outlook
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. Competitive Moats 4. Investment Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. 7. Annexures Annexures: Industry Outlook
Slide 35: India's CDMO Industry to Grow 2x Global Industry
India’s CDMO Industry to Grow 2x Global Industry Global CDMO industry (In $ bn) Levers Driving Growth of India’s CDMO Industry 278 7.2% CAGR Strategic Shift Toward Outsourcing ▪ Pharma firms outsource to CDMOs for cost savings and expertise, with CDMOs offering end-to-end drug development services C
Slide 36: India's Nutraceutical Industry: $76 BN Opportunity
India’s Nutraceutical Industry: $76 BN Opportunity Global nutraceutical industry (In $ bn) Growth Drivers of India’s Nutraceutical Industry 919 7.6% CAGR Lifestyle Shifts With Rising Health Consciousness ▪ Rising health awareness and lifestyle changes are driving demand for nutraceuticals 591 Suppor
Slide 37: Thank You
Thank You For any further information/factory visit request, please contact: Company Investor relations consultant Influx Healthtech Ltd. Capital Bridge Advisory Service Private Ltd Mr. Ashish Shah, CFO Mr. Raj Shah, CFA Mr. Hrishit Jhaveri, CFA cs@influxhealthtech.com raj@capbridge.in hrishit@capbr